GVAG
CRBU icon

Great Valley Advisor Group’s Caribou Biosciences CRBU Stock Holding History

Great Valley Advisor Group’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.6K Buy
+14,314
New +$24.6K ﹤0.01% 991

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Great Valley Advisor Group's CRBU Position: Q1 2026 in Review

Great Valley Advisor Group opened a new position in Caribou Biosciences (CRBU) in Q1 2026: 14,314 shares worth $27.6K. The stake represents ﹤0.01% of the portfolio and ranks #991 among its holdings.

137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Great Valley Advisor Group held 14,314 shares of Caribou Biosciences worth $27.6K as of Q1 2026.
  • Caribou Biosciences was a new Great Valley Advisor Group position in Q1 2026.
  • Caribou Biosciences made up ﹤0.01% of Great Valley Advisor Group's portfolio in Q1 2026, its #991 holding.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Great Valley Advisor Group's 13F filing for Q1 2026, filed 11 May 2026.